MDWD · Mediwound Ltd. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Price · MDWD
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $16.96M | $20.22M | $18.69M | $26.50M | $23.76M | $21.76M |
| Cost of Revenue | $13.71M | $17.59M | $15.11M | $13.33M | $14.99M | $14.22M |
| Gross Profit | $3.25M | $2.63M | $3.58M | $13.16M | $8.77M | $7.54M |
| R&D | $14.32M | $8.88M | $7.47M | $10.18M | $10.26M | $7.70M |
| SG&A | $8.45M | $8.20M | $6.77M | $6.92M | $6.35M | $5.46M |
| Total Operating Expenses | - | - | - | - | - | - |
| D&A | $591.0K | $630.0K | $672.0K | $426.0K | $603.0K | $554.0K |
| Operating Income | ($25.27M) | ($19.40M) | ($15.29M) | ($8.35M) | ($11.22M) | ($8.84M) |
| Interest Expense | $2.46M | $12.81M | $1.89M | $11.64M | $2.31M | $1.28M |
| Income Tax | $169.0K | $61.0K | $185.0K | $78.0K | $0 | - |
| Net Income | ($23.88M) | ($30.22M) | ($6.72M) | ($19.60M) | ($13.55M) | ($9.20M) |
| EPS - Basic | ($2.10) | ($3.03) | ($0.75) | ($2.38) | - | - |
| EPS - Diluted | ($2.10) | ($3.03) | ($0.75) | ($2.38) | - | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.80M | $9.15M | $11.87M | $33.90M | $11.05M | $17.38M |
| Accounts Receivable | $1.62M | $4.80M | $3.70M | $9.33M | $1.78M | $2.77M |
| Inventory | $4.09M | $2.69M | $2.85M | $1.96M | $1.20M | $1.38M |
| Accounts Payable | $7.65M | $5.53M | - | - | - | - |
| Current Assets | $59.96M | $52.16M | $49.70M | $45.84M | $14.95M | $26.19M |
| Total Assets | $86.25M | $73.50M | $66.46M | $50.02M | $19.74M | $31.07M |
| Current Liabilities | $25.71M | $26.54M | $10.83M | $12.06M | $10.72M | $8.27M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $42.62M | $42.34M | $34.86M | $39.10M | $23.80M | - |
| Stockholders' Equity | $43.63M | $31.15M | $31.59M | $10.91M | ($4.58M) | $7.27M |
| Retained Earnings | ($228.93M) | ($205.05M) | ($174.82M) | ($168.11M) | ($148.51M) | ($134.96M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($16.12M) | ($13.62M) | ($10.46M) | ($11.88M) | ($8.92M) | ($6.89M) |
| Investing Cash Flow | ($17.95M) | ($8.40M) | ($34.32M) | ($481.0K) | $3.55M | $17.39M |
| Financing Cash Flow | $29.62M | $19.39M | $22.92M | - | - | - |
| CapEx | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 19.2% | 13.0% | 19.1% | 49.7% | 36.9% | 34.7% |
| Operating margin | -149.0% | -95.9% | -81.8% | -31.5% | -47.2% | -40.6% |
| EBITDA margin | -145.5% | -92.8% | -78.2% | -29.9% | -44.7% | -38.1% |
| Net margin | -140.8% | -149.5% | -35.9% | -74.0% | -57.0% | -42.3% |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - |
| R&D / Revenue | 84.4% | 43.9% | 40.0% | 38.4% | 43.2% | 35.4% |
| SG&A / Revenue | 49.8% | 40.6% | 36.2% | 26.1% | 26.7% | 25.1% |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -27.7% | -41.1% | -10.1% | -39.2% | -68.6% | -29.6% |
| Return on equity | -54.7% | -97.0% | -21.3% | -179.6% | 295.7% | -126.5% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 2.33 | 1.97 | 4.59 | 3.80 | 1.39 | 3.17 |
| Quick ratio | 2.17 | 1.86 | 4.33 | 3.64 | 1.28 | 3.00 |
| Cash ratio | 0.19 | 0.34 | 1.10 | 2.81 | 1.03 | 2.10 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | -10.3x | -1.5x | -8.1x | -0.7x | -4.8x | -6.9x |
| Equity multiplier | 1.98 | 2.36 | 2.10 | 4.58 | -4.31 | 4.27 |
| Liabilities / Assets | 0.49 | 0.58 | 0.52 | 0.78 | 1.21 | - |
| Efficiency | ||||||
| Asset turnover | 0.20 | 0.28 | 0.28 | 0.53 | 1.20 | 0.70 |
| Inventory turnover | 3.35 | 6.53 | 5.31 | 6.79 | 12.49 | 10.30 |
| Days sales outstanding | 35d | 87d | 72d | 129d | 27d | 46d |
| Days inventory outstanding | 109d | 56d | 69d | 54d | 29d | 35d |
| Days payable outstanding | 204d | 115d | - | - | - | - |
| Cash conversion cycle | -60d | 28d | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | -16.1% | 8.2% | -29.5% | 11.5% | 9.2% | -31.5% |
| Revenue CAGR (3y) | -13.8% | -5.2% | -5.0% | -5.9% | 91.2% | 140.8% |
| Revenue CAGR (5y) | -4.9% | -8.6% | 40.6% | 76.2% | - | - |
| Gross profit growth (YoY) | 23.5% | -26.4% | -72.8% | 50.1% | 16.2% | -62.2% |
| Operating income growth (YoY) | -30.2% | -26.9% | -83.2% | 25.6% | -26.9% | - |
| Net income growth (YoY) | 21.0% | -350.0% | 65.7% | -44.6% | -47.4% | - |
| EPS growth (YoY) | 30.7% | -304.0% | 68.5% | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | 40.1% | -1.4% | 189.5% | - | - | -52.1% |
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
-2.25
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
4/9
Neutral
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- ✓Gross margin improved
- ✗Asset turnover improved
Peer comparison
Same SIC group: Medicinal Chemicals & Botanical Products
Comparing MediWound Ltd. against the 5 most active filers in the same SIC group.